INmune Bio Announces Published Overview Of Future Applications And Research Areas For Mesenchymal Stromal Cell Therapies, Such As INmune's CORDStrom Platform

Benzinga · 1d ago

INmune Bio, Inc. (NASDAQ:INMB) ("INmune" or the "Company"), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies, such as INmune's CORDStrom™ platform. The article, titled, "Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions," was published in the peer-reviewed journal Cytotherapy. One of the lead authors of the paper was INmune Bio's lead scientist for CORDStrom™ R&D, Dr Nikita M. Patel, M.Sci.,Ph.D.

The article, was the result of an invitation-only working party of basic, clinical and translational scientists working on MSCs and available on Cytotherapy's website, reviews the current knowledge-base and critical gaps in order to formulate experimental questions designed to enhance development of MSC therapies such as the CORDStrom™ platform. These topics included systemic delivery of MSCs, local and/or depot-delivery (which is the method for the Company's CORDStrom™ platform), and in vivo persistence.